Version 2 2021-07-14, 22:12Version 2 2021-07-14, 22:12
Version 1 2021-06-14, 16:15Version 1 2021-06-14, 16:15
figure
posted on 2021-07-14, 22:12authored byZhen Guo, Yixuan Zhang, Chang Liu, Ji Youn Youn, Hua Linda Cai
We
have previously demonstrated a novel role of bone morphogenic protein-4 (BMP4)
in inducing NOX1-dependent eNOS uncoupling, endothelial dysfunction, and
inflammatory activation in type 2 diabetes mellitus (T2DM). However, it has
remained unclear as to how BMP4 activates NOX1 and whether targeting the new
mechanistic pathway revealed is effective in preserving endothelial function in
T2DM. Here we observed that BMP4 induced marked, time-dependent increase in
physiological binding between TLR2 and NOX1 in aortic endothelial cells, as
well as increased binding of TLR2 to NOXO1. In high-fat diet fed Tlr2-/- (TLR2 knockout) mice,
the body weight gain was significantly less compared to WT (wild-type) mice
both in males and females. The high-fat diet induced increases in fasting blood
glucose levels, as well as in circulating insulin and leptin levels, were
absent in Tlr2-/- mice.
High-fat
feeding induced increases in overall fat mass, and fat mass of different
pockets were abrogated in Tlr2-/- mice.
Whereas energy intake was similar in high-fat fed WT and Tlr2-/- mice, TLR2 deficiency resulted in higher energy
expenditure attributed to improved physical activity, which was accompanied by
restored skeletal muscle mitochondrial function. In addition, TLR2 deficiency
recoupled eNOS, reduced total superoxide production, improved H4B
and NO bioavailabilities in aortas and restored endothelium-dependent
vasorelaxation. Collectively, our data strongly indicate that TLR2 plays
important roles in the development of metabolic features of T2DM, and its
related endothelial/vascular dysfunction. Therefore, targeting TLR2 may
represent a novel therapeutic strategy for T2DM, obesity and cardiovascular
complications via specific inhibition of NOX1.
Funding
This study was supported by National Institute of Health National Heart, Lung and Blood Institute (NHLBI) Grants HL077440 (HC), HL088975 (HC), HL142951 (HC) and HL154754 (HC).